NCT01087515CompletedNot Applicable
Development and Validation of Magnetic Cell Separations Techniques Using a Good Manufacturing Practice (GMP) Grade Manufacturing Process for Clinical Applications and Generation of Pre-clinical Data
Fraunhofer-Institute of Toxicology and Experimental Medicine0 sites20 target enrollmentStarted: March 1, 2010Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 20
- Primary Endpoint
- Purity of MACS® and CliniMacs® BDCA-4 positive isolated plasmcytoid dendritic cells: Percentage of CD123/BDCA-2 expressing cells
Study Overview
Brief Summary
The aim of this study is to investigate the immunomodulatory potential of Isolated Plasmacytoide Dendritic Cells (pDCs) and Regulatory T-cells (TREGs) isolated with clinical grade magnetic bead isolations techniques (MACS®) on the antigen presenting cell-induced proliferation of lymphocytes after allergen uptake in an in vitro cell culture system.
Detailed Description
pDCs as well as TREGs will be co-incubated with generated allergen presenting cells, lymphocytes, and allergen. For in vitro experimentation immune cells will be collected from blood of grass mix or house dust mite sensitized atopic/asthmatic patients.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Basic Science
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 60 Years (Adult)
- Sex
- Male
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male subjects suffering from allergic rhinitis and/or allergic asthma against timothy grass pollen (phleum pratense) and/or house dust mite.
- •age 18-60 years,
- •Nonsmokers or smokers with a history of less than 1 pack years who have not smoked within the last 12 months.
- •Positive skin prick test for timothy grass pollen (phleum pratense) and/or house dust mile within 12 months
- •Able and willing to give written informed consent
- •Hemoglobin ≥135 g/l
- •Hematocrit ≥ 0,40
- •Body weight ≥ 50 kg and Body Mass Index (BMI) within the range 19-32 kg/m²
Exclusion Criteria
- •History of lower respiratory tract infection and /or exacerbation of asthma within four weeks prior to the informed consent visit
- •Febrile illness within four week before the trial examination
- •Administration of oral, injectable, or dermal corticosteroids within the last 8 weeks or intranasal and/or inhaled corticosteroids within the last 4 weeks.
- •Intake of methylxanthines, antihistamines, antileukotrienes, oral cromolyn sodium, or oral nedocromil sodium
- •Past or present disease, which as judged by the investigator, may affect the outcome of this trial. These diseases include, but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease, hematological disease, neurological disease, endocrine disease, or pulmonary disease (including but not confined to chronic bronchitis, emphysema, tuberculosis, bronchiectasis or cystic fibrosis).
- •Specific immunotherapy (SIT) within the last two years prior to screening
- •Participation in another clinical trial 30 days prior to enrollment
- •Donation of more than 500 ml of blood in the preceding 9 weeks before the trial-examination
- •Hemoglobin below the normal lower limit
- •History of drug and/or alcohol abuse or dependence within 12 months of the trial
- •Risk of non-compliance with trial procedures
- •Suspected inability to understand the protocol requirements, instructions and trial-related restrictions, the nature, scope, and possible consequences of the trial
- •Patient is tested human immunodeficiency virus (HIV)-1/2Ab, hepatitis B surface antigen (HBsAg), or hepatitis C virus antibodies (HCV-Ab) positive
Outcomes
Primary Outcomes
Purity of MACS® and CliniMacs® BDCA-4 positive isolated plasmcytoid dendritic cells: Percentage of CD123/BDCA-2 expressing cells
Secondary Outcomes
No secondary outcomes reported
Investigators
Similar Trials
Completed
Not Applicable
Identification and Analysis of Immunomodulatory Molecules in Patients With Hematologic Disorders and Healthy VolunteersHematologic DiseasesHealthy VolunteersNCT00223483The University of Texas Health Science Center at San Antonio512
Completed
Not Applicable
Immunophenotyping of Plasma Cells and Immune Effector Cells in Peripheral Whole Blood and Bone Marrow Samples From Multiple Myeloma (MM) PatientsMultiple MyelomaNCT05428163Assistance Publique Hopitaux De Marseille20
Completed
Not Applicable
Anti-Pseudomonas Immune Status and Dendritic Cell Preparation in Normal IndividualsHealthyNCT00320164Weill Medical College of Cornell University8
Completed
Not Applicable
A Development Plan of in Vitro Diagnostics of Immuno Magnetic Reduction Assay - A Rapid Etection Kit of Enterobacteraceae in Blood or Blood CultureImmuno Magnetic ReductionNCT01255098Taipei Medical University WanFang Hospital300
Completed
Not Applicable
Determination of Blood Tumor CellsLeukemia, Lymphocytic, Chronic, B-CellAbnormalities Cell EpithelialNCT04290923University of Zurich71